Problems Processing Sensory Information Linked to MS Severity, Difficulties in Daily Life, Study Finds
People with multiple sclerosis (MS) — both with and without cognitive impairments — have trouble processing sensory information, which…
Articles by Ana Pena PhD
Protein That Helps Cells Break Down Sugar Also Promotes Inflammation, Study Suggests
A protein involved in cell metabolism, called PKM2, was found to be central to switching ‘on’ immune cells…
Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says
Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary…
Acthar Gel Quite Effective at Resolving Relapses as Alternative to Corticosteroids, Study Reports
Acthar Gel (repository corticotropin injection) is more effective for treating flares in multiple sclerosis (MS)…
Siemens Healthineers Joins with Quanterix to Develop Blood Tests for NfL Levels
Siemens Healthineers has signed a license and supply agreement with Quanterix that helps it in developing blood tests…
EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals with ICUs
Seven months after starting a safety review of Lemtrada (alemtuzumab), the…
Mutations in 3 Genes Linked to Vision Loss and MS Severity in Hopkins Study
Mutations in genes related to the immune system’s first line of defense are associated with a greater likelihood of more…
Interferons Superior to Glatiramer Acetate, and Tysabri More Effective than Gilenya for RRMS, Real-world Study Finds
Interferon therapy (brand names Avonex, Betaseron, and others)…
Medicinal Cannabinoids Not Effective for Mental Disorders, Small Relief on MS Anxiety, Analysis Suggests
A joint analysis of 83 studies, involving 3,000 people, concluded that there is “scarce evidence” to say that the use…
Twice Daily Dosing and Side Effects Top Reasons Patients Seen to Stop Tecfidera in Small Study
A twice-daily dosing schedule and side effects like nausea and flushing are key reasons why more than 10% of multiple…
Potential RRMS Fumarate Treatment Free of ‘Flush’ Effect to Enter Trial in 2020, Vitalis Says
Vitalis is planning to open a pivotal clinical trial into its new formulation of fumarate, called VTS-72, that has shown promise…
GAL Gene Variant May Put MS Patients at Risk for Rapidly Progressive Disease, Study Suggests
A genetic variant in the galanin gene (GAL) appears to…
#ECTRIMS2019 – Are Injectables Inappropriate for Active Relapsing MS Treatment?
With more high-efficacy therapies becoming available, is it now inappropriate to prescribe older injectables — interferon beta and glatiramer acetate…
#ECTRIMS2019 – Ofatumumab Part of ‘Magnificent Success Story’ for MS, ASCLEPIOS Trial Investigator Says
Ofatumumab, an investigational B-cell therapy being developed by Novartis, demonstrated encouraging results in lowering relapse rates and active brain…
Immunic Therapeutics Fully Enrolls Phase 2 Trial of Oral IMU-838, Potential RRMS Treatment
Immunic Therapeutics announced that a Phase 2 clinical trial of IMU-838, its experimental oral therapy for relapsing-remitting multiple sclerosis (RRMS), is…
Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports
Prescriptions of two multiple sclerosis (MS) treatments —  Merck KGaA‘s Mavenclad (cladribine) and Roche‘s Ocrevus (ocrelizumab)…
CMSC Grant to Support Kessler Foundation Study of Low-risk Exercise in MS
The Consortium of Multiple Sclerosis Centers (CMSC) has awarded a grant to Kessler Foundation researchers, supporting a pilot…
#ECTRIMS2019 – Is Rituximab a Reasonable Option for MS Patients? No, Researcher Says
Editor’s note: This is the third story in a three-part report examining the question, “Is rituximab a reasonable alternative treatment…
#ECTRIMS2019 – Is Rituximab a Reasonable Option for MS Patients? Yes, Researcher Says
Editor’s note: This is the second story in a three-part report examining the question, “Is rituximab a reasonable alternative treatment…
#ECTRIMS2019 – Is Rituximab a Reasonable Option for MS Patients?
Editor’s note: This is the first story in a three-part report examining the question, “Is rituximab a reasonable alternative treatment…
#ECTRIMS2019 – Mollii Suit Can Ease Muscle Stiffness and Improve Movement, Reports State
Mollii, an electrostimulation suit, can help reduce muscle stiffness, or spasticity, and its associated pain, as well as improve…
#ECTRIMS2019 – Should Vitamin D Supplements Be Recommended for MS? No, Researcher Says
Editor’s note: This is the third story in a three-part report examining the question “Should vitamin D supplements be recommended…
#ECTRIMS2019 – Should Vitamin D Supplements Be Recommended for MS? Yes, Researchers Say
Editor’s note: This is the second story in a three-part report examining experts’ answers to the question “Should vitamin D…
#ECTRIMS2019 – Should Vitamin D Supplements Be Recommended for MS?
Editor’s note: This is the first story in a three-part report examining the question “Should vitamin D supplements be recommended…
#ECTRIMS2019 – Mayzent’s Benefits from a Patient Perspective a ‘Key Question,’ Says EXPAND’s Principal Investigator
The most recent data continue to support Mayzent‘s (siponimod) benefits and provide more insights on how this therapy can…
#ECTRIMS2019 – Ahead for Mavenclad: Fuller Understanding of What Makes It ‘Unique,’ Serono Exec Says in Interview
Real-world data continues to support the safety and effectiveness of Mavenclad (cladribine tablets) in treating multiple sclerosis (MS), and several studies underway…
#ECTRIMS2019 – Ocrevus Living Up to ‘Game-changing’ Moniker, Genentech’s Hideki Garren Says in Interview
Two years after the approval of Ocrevus (ocrelizumab), the latest data continue to support the benefits of the so-called…
#ECTRIMS2019 – Ozanimod’s ‘Key Advantages’ May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen
Celgene‘s oral ozanimod, if approved, could be a first-line oral treatment option for people with relapsing…
#ECTRIMS2019 — Ponesimod Superior to Aubagio in Relapsing MS, OPTIMUM Trial Shows
Actelion‘s ponesimod, an investigational oral treatment, is superior to Sanofi‘s Aubagio (teriflunomide) in lessening the frequency…
#ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds
Continuing Tysabri (natalizumab) treatment up to week 28 of pregnancy, and restarting soon after birth, reduces the risk…